SARS-CoV-2 infection perturbs the gastrointestinal tract and induces modest microbial translocation across the intestinal barrier
Authors:
- 22 October 2024
- journal article
- research article
- Published by American Society for Microbiology in Journal of Virology
- Vol. 98 (10) , e0128824
Abstract
SARS-CoV-2 infects via the respiratory tract, but COVID-19 includes an array of non-respiratory symptoms, among them gastrointestinal (GI) manifestations such as vomiting and diarrhea. Here we investigated the GI pathology of SARS-CoV-2 infections in rhesus macaques and humans. Macaques experienced mild infection with USA-WA1/2020 and shed viral RNA in the respiratory tract and stool, including subgenomic RNA indicative of replication in the GI tract. Intestinal immune cell populations were disturbed, with significantly fewer proliferating (Ki67+) jejunal B cells in SARS-CoV-2-infected macaques than uninfected ones. Modest translocation of bacteria/bacterial antigen was observed across the colonic epithelium, with a corresponding significant increase in plasma soluble CD14 (sCD14) that may be induced by LPS. Human plasma demonstrated significant decreases in interleukin (IL)-6 and sCD14 upon recovery from COVID-19, suggesting resolution of inflammation and response to translocated bacteria. sCD14 significantly positively correlated with zonulin, an indicator of gut barrier integrity, and IL-6. These results demonstrate that GI perturbations such as microbial translocation can occur in even mild SARS-CoV-2 infections and may contribute to the COVID-19 inflammatory state. IMPORTANCE: This study investigates gastrointestinal (GI) barrier disruption in SARS-CoV-2 infections and how it may contribute to disease. We observed bacteria or bacterial products crossing from the colon interior (the lumen) to the lamina propria during SARS-CoV-2 infection in macaques. Bacteria/bacterial products are tolerated in the lumen but may induce immune responses if they translocate to the lamina propria. We also observed a significant increase in soluble CD14, which is associated with an immune response to bacterial products. In addition, we observed that humans recovering from COVID-19 experienced a significant decrease in soluble CD14, as well as the inflammatory marker interleukin (IL)-6. IL-6 and sCD14 correlated significantly across macaque and human samples. These findings suggest that SARS-CoV-2 infection results in GI barrier disruption that permits microbial translocation and a corresponding immune response. These findings could aid in developing interventions to improve COVID-19 patient outcomes.Keywords
Funding Information
- HHS | NIH | NIAID | Division of Intramural Research (ZIAAI001029)
This publication has 49 references indexed in Scilit:
- Intestinal immunological events of acute and resolved SARS-CoV-2 infection in non-human primatesMucosal Immunology, 2023
- Gut microbiome dysbiosis in antibiotic-treated COVID-19 patients is associated with microbial translocation and bacteremiaNature Communications, 2022
- Human small intestinal infection by SARS-CoV-2 is characterized by a mucosal infiltration with activated CD8+ T cellsMucosal Immunology, 2021
- Association between detectable SARS‐COV‐2 RNA in anal swabs and disease severity in patients with coronavirus disease 2019Journal of Medical Virology, 2020
- Imbalanced Host Response to SARS-CoV-2 Drives Development of COVID-19Cell, 2020
- Prolonged presence of SARS-CoV-2 viral RNA in faecal samplesThe Lancet Gastroenterology & Hepatology, 2020
- Interleukin-6 as an early diagnostic marker for bacterial sepsis in patients with liver cirrhosisJournal of Critical Care, 2015
- Human gut microbiome viewed across age and geographyNature, 2012
- Microbial translocation is a cause of systemic immune activation in chronic HIV infectionNature Medicine, 2006
- Peak SIV replication in resting memory CD4+ T cells depletes gut lamina propria CD4+ T cellsNature, 2005